To The Moon

$Inhibrx Biosciences(INBX)$ $Deckers Outdoor(DECK)$ $Beyond Meat, Inc.(BYND)$ 💹🔥🧬 From Biotech Euphoria to Retail Pain: INBX, DECK, BYND in Focus 📉🧠💰

I’m watching these setups closely into next weekend as volatility compresses across sectors and capital rotates into high-beta names. I’m seeing traders reposition portfolios where conviction meets chaos, and that’s where the alpha lives.

The reason this setup matters now is that traders are rotating aggressively between high-beta gainers and short-fuelled laggards as macro catalysts tighten liquidity into month-end.

🧬 InhibRx ($INBX) rockets +102% on clinical optimism

InhibRx Biosciences (NASDAQ: INBX) surged 102.01% to $56.00 on 27Oct25 NZT after its therapeutic antibody platform announcement sparked a flood of speculative bids. Volume was nearly triple average, signalling large institutional rotation into small-cap biotech risk. RSI is above 85 on the 4H, MACD widening positively, and price now trades well above the upper Keltner and Bollinger bands.

Revenue last quarter grew 31% year on year, though losses narrowed modestly. EMA-13 and EMA-55 crossovers confirm bullish momentum, while short-term resistance sits at $57.29 and support at $45.80.

Options flow was heavily concentrated in $60 calls expiring 15Nov, with net premium above $2.3M. The skew is now sharply positive, reflecting speculative upside.

Momentum traders see this as a continuation if $52.60 holds. My base case is for consolidation between $52–$60 before another leg higher; invalidation comes on a break below $48. Macro tightening or biotech ETF rebalancing could introduce near-term volatility.

👟 Deckers ($DECK) retreats as consumer sentiment cools

Deckers Outdoor Corporation (NYSE: DECK) fell 15.21% to $87.17 on 27Oct25 NZT following weaker forward sales guidance in the footwear and apparel segment. Revenue growth decelerated to +5% YoY from +15% prior quarter, and gross margins compressed by 90 bps due to higher input costs.

Technically, DECK remains below its EMA-55 with price tracking the lower Bollinger boundary. RSI sits at 33, suggesting a mild oversold condition, but MACD remains bearish.

Put flow dominated with $85 and $80 strikes dated 22Nov, showing $1.8M net bearish premium. The tape indicates systematic outflows rather than panic, implying portfolio de-risking.

I expect a base to form between $82–$88, contingent on macro retail data and holiday order flows. My base case is 60% probability of rebound to $97 if RSI recovers above 45, with 40% chance of further downside if Fed commentary tightens discretionary spending outlooks.

🥩 Beyond Meat ($BYND) sinks on revenue collapse and short pressure

Beyond Meat (NASDAQ: BYND) dropped 23.06% to $2.01 on 27Oct25 NZT, extending its multi-month decline. The company reported Q3 revenue of $63.8M, missing estimates by 11%, with gross margin at just 4%. EPS came in at -$0.28, below consensus.

Technically, BYND rejected $5.50 after a short-covering rally, with RSI back to 39 and MACD rolling negative. The EMA cluster near $2.70 now acts as resistance. The sharp contraction back under the Keltner midline suggests fading momentum.

Options flow spiked in $2 puts expiring 01Nov, reflecting a net bearish skew with over $900K premium.

Short-term, I’m watching $1.80 as critical support. Base case (55%) is for a volatile retest of $2.60 if short interest triggers another squeeze; downside risk (45%) resumes below $1.80 amid weakening liquidity and shrinking retail appetite for loss-making consumer brands.

I’m reading these moves as part of a broader volatility regime shift where biotech and consumer cyclicals are diverging sharply. INBX’s speculative breakout mirrors risk-on appetite in smaller caps, while DECK and BYND show the opposite end of liquidity compression. Sector dispersion is widening, and disciplined traders can exploit these misalignments with defined risk parameters and flow confirmation.

📊 Momentum Extremes Across the Broader Watchlist

🟣 Overbought setups: I’m closely watching $INVU, $ARMP, and $TRML, each flashing elevated RSI readings above 70 that hint at exhaustion risk.

🟢 Oversold opportunities: $ITGR, $RC, and $UHG are hovering near potential mean-reversion zones that could attract dip-buyers as momentum cools.

🔴 Short-interest pressure: $BYND and $KSS remain the most combustible; both have conditions ripe for gamma-driven squeezes if volume spikes align with options delta hedging.

⚡️ Keep an eye on $GSIT

Cornell validated its APU tech matching GPU performance at 98% less energy. That’s not just a creepy warning; that’s a shift worth watching 👀

I’m reading these moves as part of a broader volatility regime shift where biotech and consumer cyclicals are diverging sharply. INBX’s speculative breakout mirrors risk-on appetite in smaller caps, while DECK and BYND show the opposite end of liquidity compression. Sector dispersion is widening, and disciplined traders can exploit these misalignments with defined risk parameters and flow confirmation.

📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀

Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀

@Daily_Discussion @Tiger_comments @TigerPM @TigerObserver @TigerStars